Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/8/2022 | $13.00 | Buy | The Benchmark Company |
| 11/4/2021 | $12.00 | Equal-Weight → Overweight | Stephens & Co. |
| 7/16/2021 | $12.00 | Hold → Buy | Stifel |
10-Q - DNOW Inc. (0001599617) (Filer)
8-K - DNOW Inc. (0001599617) (Filer)
10-Q - DNOW Inc. (0001599617) (Filer)
4 - DNOW Inc. (0001599617) (Issuer)
4 - DNOW Inc. (0001599617) (Issuer)
4 - DNOW Inc. (0001599617) (Issuer)
Stifel analyst Nathan Jones maintains Dnow (NYSE:DNOW) with a Buy and raises the price target from $16 to $17.
Susquehanna analyst Charles Minervino maintains Dnow (NYSE:DNOW) with a Neutral and lowers the price target from $15 to $14.
5 analysts have shared their evaluations of Dnow (NYSE:DNOW) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 1 0 0 3M Ago 1 0 1 0 0 Analysts have recently evaluated Dnow and provided 12-month price targets. The average target is $15.6, accompanied by a high estimate of $18.00 and a low estimate of $13.00. This upward trend is evident, with t
SC 13G/A - DNOW Inc. (0001599617) (Subject)
SC 13G/A - DNOW Inc. (0001599617) (Subject)
SC 13G/A - DNOW Inc. (0001599617) (Subject)
The Benchmark Company initiated coverage of Now with a rating of Buy and set a new price target of $13.00
Stephens & Co. upgraded NOW from Equal-Weight to Overweight and set a new price target of $12.00
Stifel upgraded NOW from Hold to Buy and set a new price target of $12.00
DUBAI, UAE, May 8, 2023 /PRNewswire/ -- Borets International Limited, a global leader in artificial lift engineering, manufacturing, sales, and servicing of electric submersible pumps (ESP), announced the growing and evolving Company has undergone restructuring to reach this exciting juncture where the international business is a distinct and separate division. Accordingly, the rebranding of the company to Levare International Limited (Levare or Company) better aligns with the forward-thinking mindset of new leadership. This change reflects our growing portfolio of artificial lift solutions offered to our global clients within the oil & gas, mining, geothermal and municipal industries.
NOW Inc. (NYSE:DNOW) announced today that Karen David-Green has been appointed to the Company's Board of Directors effective March 24, 2023. Ms. David-Green's term will expire at the 2023 annual stockholders' meeting. Ms. David-Green has served as the Chief Communications, Stakeholder and Sustainability Officer at Expro Group, a publicly traded company listed on the New York Stock Exchange, since 2021. Prior to joining Expro Group, Ms. David-Green was part of Weatherford International plc for ten years, where she last served as Senior Vice President, Stakeholder Engagement & Chief Marketing Officer. Prior to joining the energy industry, Ms. David-Green spent 15 years on Wall Street, where
NOW Inc. (NYSE:DNOW) announced today that Sonya Reed has been appointed to the Company's Board of Directors effective August 11, 2021. Ms. Reed's term will expire at the 2022 annual stockholders' meeting. Ms. Reed has served as the Senior Vice President of Human Resources and Corporate Communications of Phillips 66, a publicly traded company listed on the New York Stock Exchange, since 2015. From 2011 to 2015, Ms. Reed was with General Cable, where she last served as Executive Vice President, Chief Human Resources Officer. Ms. Reed began her career at Zurich Financial Services, where she held several positions of increasing responsibility, the last of which was Vice President of Human Reso
Earnings Conference Call November 7, 2024 8:00 a.m. CT 1 (888) 660-6431 (within North America) 1 (929) 203-2118 (outside of North America) Access Code: 7372055 Webcast: ir.dnow.com DNOW Inc. (NYSE:DNOW) announced results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Revenue was $606 million for the third quarter of 2024 Net income attributable to DNOW Inc. was $13 million, or $0.12 per diluted share, for the third quarter of 2024 Non-GAAP net income attributable to DNOW Inc. excluding other costs was $22 million, or $0.21 per diluted share, for the third quarter of 2024 EBITDA excluding other costs was $42 million or 6.9% of revenue for the third q
DNOW Inc. (NYSE:DNOW) has scheduled a conference call to discuss the results for the third quarter of 2024 on Thursday, November 7, 2024 at 8:00 am (US Central Time). Financial results for the third quarter ending on September 30, 2024 are expected to be released that morning before the market opens. The call will be broadcast through the Investor Relations link on DNOW's web site at ir.dnow.com on a listen-only basis. Listeners should log in prior to the start of the call to register for the webcast. A replay of the call will be available online for thirty days following the conference. Participants may also join the conference call by dialing 1-888-660-6431 within North America or 1-929-
Earnings Conference Call August 7, 2024 8:00 a.m. CT 1 (888) 660-6431 (within North America) 1 (929) 203-2118 (outside of North America) Access Code: 7372055 Webcast: ir.dnow.com DNOW Inc. (NYSE:DNOW) announced results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights Revenue was $633 million for the second quarter of 2024 Net income attributable to DNOW Inc. was $24 million, or $0.21 per diluted share, for the second quarter of 2024 Non-GAAP net income attributable to DNOW Inc. excluding other costs was $28 million, or $0.25 per diluted share, for the second quarter of 2024 EBITDA excluding other costs was $50 million or 7.9% of revenue for the sec
For Immediate Release: December 15, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA updated the breast implants web pages to share the latest information on: Risks and complications related to breast implants Reports of squamous cell carcinoma (SCC), various lymphomas other than Breast Implants Associated Anaplastic Large
For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Friday, the FDA approved Medtronic’s Aurora EV-ICD System for the treatment of patients who have experienced, or are at significant risk of developing, life-threatening abnormally fast heart rhythms (ventricular tachyarrhythmias). The system is composed of
For Immediate Release: June 09, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA provided information to health care providers and facilities on oxygenator devices used in extracorporeal circulation. The FDA issued this letter to help ensure that health care providers and facilities are aware of a recall notice by Getinge/Maque
Earnings Conference Call November 7, 2024 8:00 a.m. CT 1 (888) 660-6431 (within North America) 1 (929) 203-2118 (outside of North America) Access Code: 7372055 Webcast: ir.dnow.com DNOW Inc. (NYSE:DNOW) announced results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Revenue was $606 million for the third quarter of 2024 Net income attributable to DNOW Inc. was $13 million, or $0.12 per diluted share, for the third quarter of 2024 Non-GAAP net income attributable to DNOW Inc. excluding other costs was $22 million, or $0.21 per diluted share, for the third quarter of 2024 EBITDA excluding other costs was $42 million or 6.9% of revenue for the third q
DNOW Inc. (NYSE:DNOW) has scheduled a conference call to discuss the results for the third quarter of 2024 on Thursday, November 7, 2024 at 8:00 am (US Central Time). Financial results for the third quarter ending on September 30, 2024 are expected to be released that morning before the market opens. The call will be broadcast through the Investor Relations link on DNOW's web site at ir.dnow.com on a listen-only basis. Listeners should log in prior to the start of the call to register for the webcast. A replay of the call will be available online for thirty days following the conference. Participants may also join the conference call by dialing 1-888-660-6431 within North America or 1-929-
Earnings Conference Call August 7, 2024 8:00 a.m. CT 1 (888) 660-6431 (within North America) 1 (929) 203-2118 (outside of North America) Access Code: 7372055 Webcast: ir.dnow.com DNOW Inc. (NYSE:DNOW) announced results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights Revenue was $633 million for the second quarter of 2024 Net income attributable to DNOW Inc. was $24 million, or $0.21 per diluted share, for the second quarter of 2024 Non-GAAP net income attributable to DNOW Inc. excluding other costs was $28 million, or $0.25 per diluted share, for the second quarter of 2024 EBITDA excluding other costs was $50 million or 7.9% of revenue for the sec